RMTI — Rockwell Medical, Inc.

Summary of Rockwell Medical, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Net Sales: $18.3 million, a 15% increase from Q3 2025 but a 26% decrease from Q4 2024 ($24.7 million).
• Full Year 2025 Net Sales: $69.3 million, down 32% from $101.5 million in 2024.
• Q4 2025 Gross Profit: $3.9 million, up 70% from Q3 2025 and consistent with Q4 2024.
• Full Year 2025 Gross Profit: $11.7 million, down from $17.5 million in 2024.
• Q4 2025 Gross Margin: 21%, one of the highest in company history, up from 14% in Q3 2025 and 15% in Q4 2024.
• Full Year 2025 Adjusted EBITDA: Positive $300,000, compared to $5 million in 2024; Q4 2025 Adjusted EBITDA was $1 million.
• Cash Position: Ended 2025 with $25 million, an increase from $173,000 in March 2025.

2. Strategic Updates and Business Highlights

• Rockwell Medical successfully diversified its customer base, serving approximately 300 customers, including major dialysis providers.
• Extended agreements with key customers like DaVita and Fresenius, with DaVita increasing purchase volumes.
• Established a multi-year agreement with Innovative Renal Care, enhancing product supply reliability.
• Expanded product portfolio with a new single-use bicarbonate cartridge, projected to generate $1 million in net sales in 2026.
• Operational improvements led to significant margin expansion and cash flow positivity in Q4 2025.

3. Forward Guidance and Outlook

• For 2026, Rockwell Medical projects Adjusted EBITDA between $1 million and $2 million and expects to remain profitable and generate positive cash flow.
• Anticipates further growth from ongoing negotiations with large customers, which could enhance net sales and gross margins.
• Long-term goals include achieving annual net sales above $100 million by 2029 and gross margins approaching 30%.

4. Bad News, Challenges, or Points of Concern

• Full year net sales declined significantly due to reduced purchase volumes from key customers.
• The company reported a net loss of $5.3 million for 2025, compared to a loss of $500,000 in 2024, impacted by noncash expenses and restructuring costs.
• Competitive pressures from other suppliers, particularly Fresenius and Nipro, could impact market share and pricing strategies.
• The ongoing need to stabilize and grow customer relationships, particularly with DaVita, remains a critical focus.

5. Notable Q&A Insights

• DaVita has provided forecasts for 2026, indicating consistent purchasing volumes, which is seen as a positive sign for future relations.
• The company is actively pursuing additional customer acquisitions in the West, with expectations for growth in that region.
• The at-home dialysis market is currently about 10% of the overall market, with Rockwell positioned to benefit as this segment grows.
• Competitive advantages include high-quality products and efficient logistics, which are critical in maintaining customer relationships and expanding market share.

Overall, Rockwell Medical demonstrated resilience in navigating operational changes and maintaining profitability, while also setting a strategic path for future growth despite facing significant challenges in sales and competition.